NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
In June 2024, multiple state regulators took joint action against Plutus Financial, Inc (Abra) ordering Abra to cease and desist certain operations in the U.S. and reimburse customers of virtual ...
Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...
IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...
Innovative models of germline genetic evaluation are needed for patients with MDS/AML to address systems-level barriers to care, including the development of inpatient genetic counseling and testing ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results